JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Ertugliflozin (formerly known as also known as PF-04971729; trade name: Steglatro) is an orally active and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2). In 2017, Ertugliflozin was approved by FDA to improve glycemic control in adults with type 2 diabetes mellitus. First-in-human studies after oral administration indicated that the human pharmacokinetics/dose predictions for PF-04971729 were in the range that is likely to yield a favorable pharmacodynamic response. Ertugliflozin (1-25?mg/day) improved glycaemic control, body weight and blood pressure in patients with T2DM suboptimally controlled on metformin, and was well tolerated.
References: J Med Chem. 2011 Apr 28; 54(8):2952-60; Drug Metab Dispos. 2013 Feb; 41(2):445-56; Drug Metab Dispos. 2011 Sep; 39(9):1609-19.
Related CAS#:1210344-83-4 (Ertugliflozin pidolate)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!